Synergistic and chemosensitizing effects of bovine lactoferrin or muramyl dipeptide in Ehrlich solid tumor-bearing mice treated with cisplatin | ||
| Egyptian Journal of Cancer and Biomedical Research | ||
| Article 8, Volume 5, Issue 1, March 2021, Pages 75-94 PDF (10.29 M) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/jcbr.2020.32770.1047 | ||
| Authors | ||
| Dalia Morsi* 1; Mohamed Labib Salem2; Hany Ibrahim1; Gamalat Osman1; Azza Mohamed1; Amany Nofal1 | ||
| 1Zoology Department, Faculty of Science, Menoufia University, Shibin El-Kom, Egypt | ||
| 2Immunology and Biotechnology Division, Department of Zoology, Faculty of Science, Tanta University, Egypt | ||
| Abstract | ||
| Background: Despite the effectiveness of anti-cancer chemotherapy, it is associated with serious adverse side effects and the development of drug-resistance mechanisms. Immune dysfunction is considered one of the most serious adverse effects of anti-cancer chemotherapy, which increases the susceptibility of the patients to infection. Co-administration of immunomodulatory agents as adjuvant therapy with chemotherapy will result in better anti-tumor responses with fewer side effects. Aim: This study was designed to evaluate the ameliorative effects of bovine lactoferrin (bLF) and muramyl dipeptide (MDP) against toxicity induced by cisplatin in tumor-bearing mice. Materials and Methods: In this study, MDP or bLF was co-treated with cisplatin in mice bearing Ehrlich solid tumor (EST). Results: Co- treatment of cisplatin with MDP or bLF enhanced the anti-tumor effects of cisplatin to induce a reduction of the tumor size, proliferative capabilities of tumor cells accompanied by an elevation in the apoptotic profile of tumor cells. Moreover, co- treatments of Cisplatin with bLF or MDP reversed the Cisplatin-induced immune suppression and partially restored splenocyte proliferation, immune organ indices, hematological profile, liver and kidney functions, and histological structure. Conclusion: Both bLF and MDP were able to act as adjuvant therapy with anti-cancer chemotherapy through their abilities to enhance the chemotherapy curative effects, modulate the immune response against tumor cells, and to some extent ameliorate the adverse toxic effects of the chemotherapy. | ||
| Keywords | ||
| Cisplatin; Immunohistochemistry; Immunosuppression; Lactoferrin; Muramyl dipeptide | ||
|
Statistics Article View: 634 PDF Download: 686 |
||
